AIM ImmunoTech Inc.

Equities

AIM

US00901B1052

Biotechnology & Medical Research

Delayed Nyse Other stock markets 07:57:35 17/07/2024 pm IST			5-day change	1st Jan Change
0.3851 ^USD	-3.72%		+7.27%	-12.46%

05/06	Transcript : AIM ImmunoTech Inc. - Special Call
16/05	Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024

AIM ImmunoTech : 2022 Top Picks Conference Presentation - January 26, 2022

January 28, 2022 at 09:13 pm IST

2022 Top Picks Conference

January 26, 2022

Thomas K. Equels, CEO

AIM ImmunoTech Inc.

View the full presentation here.

Attachments

Original Link
Original Document
Permalink

Disclaimer

AIM ImmunoTech Inc. published this content on 28 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 January 2022 15:42:08 UTC.

Latest news about AIM ImmunoTech Inc.

Transcript : AIM ImmunoTech Inc. - Special Call	05/06
Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024	16/05
AIM ImmunoTech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed	29/04	MT
AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	10/04	CI
Transcript : AIM ImmunoTech Inc., Q4 2023 Earnings Call, Apr 02, 2024	02/04
North American Morning Briefing : Stocks Seen -2-	02/04	DJ
AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04	CI
Transcript : AIM ImmunoTech Inc. - Special Call	20/03
AIM ImmunoTech Inc. announced that it has received $3.30125 million in funding	20/02	CI
AIM ImmunoTech Inc. announced that it has received $2.5 million in funding	16/02	CI
Aim Immunotech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions	08/02	CI
AIM ImmunoTech Says First Subject Enrolled in Phase 1b/2 Study of Pancreatic Cancer Combination Therapy	22/01	MT
Declaration of Voting Results by AIM ImmunoTech	11/01	CI
Transcript : AIM ImmunoTech Inc. - Pre Recorded Special Call	10/01
Kellner Group Issues a Statement to the Shareholders	04/01	CI
Sector Update: Health Care	30/12	MT
AIM ImmunoTech Says Delaware Court Rules in Its Favor, Deeming Activist Group's Board Nominations 'Invalid'	29/12	MT
Sector Update: Health Care Stocks Advance Late Afternoon	30/12	MT
Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board?s Determination that Activist Group?s Nominations Are Invalid	29/12	CI
AIM ImmunoTech Provides Update Regarding Annual Meeting	29/11	CI
AIM ImmunoTech Gets US Patents for Ampligen Cancer, ME/CFS Treatment Methods	27/11	MT
AIM ImmunoTech Treats Last Participant in Phase 2 Study of Ampligen for Potential Treatment of Post-COVID Fatigue	22/11	MT
AIM ImmunoTech Inc. Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions	21/11	CI
AIM ImmunoTech Mails Letter to its Shareholders	21/11	CI

Chart AIM ImmunoTech Inc.

Duration

Period

More charts

Company Profile

AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

Sector

Biotechnology & Medical Research

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for AIM ImmunoTech Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.4 USD

Average target price

3.583 USD

Spread / Average Target

+795.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AIM IMMUNOTECH INC.	-12.46%	22.85M
VERTEX PHARMACEUTICALS INCORPORATED	+19.98%	126B
REGENERON PHARMACEUTICALS, INC.	+24.78%	118B
ARGENX SE	+24.22%	27.87B
BIONTECH SE	-17.01%	20.95B
GENMAB A/S	-14.90%	16.92B
BEIGENE, LTD.	-13.73%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+10.06%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+53.18%	14.08B

Bio Therapeutic Drugs